Wolfe Research Initiates Coverage On ResMed with Outperform Rating, Announces Price Target of $280
Wolfe Research analyst Mike Polark initiates coverage on ResMed (NYSE:RMD) with a Outperform rating and announces Price Target of $280.
Ominous Death Cross Forms On ResMed’s Chart
If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Citigroup Upgrades ResMed to Buy
Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
EXCLUSIVE: ResMed CEO, Mick Farrell Now Interviewing On Benzinga’s Live YouTube TV
Click To Tune In Here... https://www.youtube.com/watch?v=jWvXpUHTfMY
ResMed’s Return on Invested Capital Overview
According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01% change since Q1.
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
ResMed Inc (NYSE: RMD) revealed a
RBC Capital Upgrades ResMed to Sector Perform, Announces $241 Price Target
RBC Capital upgrades ResMed (NYSE:RMD) from Underperform to Sector Perform and announces $241 price target.
ResMed Q2 Adj. EPS $1.47 Misses $1.52 Estimate, Sales $894.90M Miss $935.25M Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $1.47 per share which missed the analyst consensus estimate of $1.52 by 3.29 percent. This is a 4.26 percent increase over earnings of $1.41 per share from the same period
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: